
|Videos|January 5, 2016
Dr. Christopher Twelves on Eribulin Mesylate in Combination Therapies for Breast Cancer
Author(s)Christopher Twelves, MD
Twelves said historically, chemotherapy combinations have been created utilizing empirical evidence, which he says is not a sound rationale for the combinations. He adds that due to certain biological properties of eribulin mesylate, the treatment warrants further investigation as a combination therapy.
Advertisement
Christopher Twelves, MD, professor of Clinical Cancer Pharmacology and Oncology at the Leeds Institute of Cancer and Pathology, St James's Institute of Oncology, Leeds, UK, discusses the potentials for eribulin mesylate (Halaven) to be used in combination with other therapies in the treatment of breast cancer.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Gedatolisib for Advanced Breast Cancer
2
RFS Benefit Sustained at 5 Years for Intismeran Autogene in Melanoma
3
FDA Grants BTD to Sofetabart Mipitecan for Platinum-Resistant Ovarian Cancer
4
Zenocutuzumab Offers Durable Benefit After Progression in NRG1+ GI Tumors
5














































